Last checked at 18 May 2022 07:00
This announcement contains inside information for the purposes of Article 7 of EU Regulation No. 596/2014, which forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended).
18 May 2022
Graft Polymer (UK) Plc
("Graft Polymer", the "Company", and together with its subsidiaries, the "Group")
Director Share Purchase
Graft Polymer (UK) Plc (LSE: GPL), a business focused on the development of polymer modification, biological supplements and drug delivery systems, announces that on 17 May 2022 Sputnik Enterprises Limited, a company in which Roby Zomer, the Non-Executive Chairman of Graft Polymer, holds a 50% beneficial interest, acquired 462,500 Ordinary Shares at an average price of 16.0054 pence per Ordinary Share. Following this acquisition of shares, Roby Zomer has a total beneficial interest in 6,326,510 Ordinary Shares*, representing approximately 6.08% of the total issued share capital of the Company.
*4,576,163 Ordinary Shares are held in the name of Chitta Lu Limited and 1,750,347 Ordinary Shares are held in the name of Sputnik Enterprises Limited which Mr. Zomer has a 50% beneficial interest in
For more information, please visit https://www.graftpolymer.com or contact:
Graft Polymer (UK) Plc | via Tavistock |
Roby Zomer, Chairman | |
Yifat Steuer, CFO | |
Turner Pope Investments (Broker) | +44 20 3657 0050 |
James Pope | |
Andy Thacker | |
Tavistock (Public Relations) | +44 207 920 3150 |
Heather Armstrong | graftpolymer@tavistock.co.uk |
Katie Hopkins |
About Graft Polymer
Graft Polymer is a UK incorporated holding company with an innovative research and manufacturing facility, based in Slovenia. The core business of the Group comprises polymer modification and drug delivery systems developments. Established in 2017, the Group has already introduced more than 50 products to the market.
The Group has developed a proprietary set of polymer modification technologies, which can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.
In particular, the Group's techniques allow the combination of otherwise incompatible polymers, facilitating the creation of polymer composites engineered at a molecular level, that combine the attractive properties of different input materials. This enables customers to receive a synergism of properties in polymer composites.
The solutions and products offered by the Group are designed to improve performance, reduce raw materials consumption, and enhance the physical characteristic values of finished products or improve or modify their chemical interaction. In the past several years, there has been increased emphasis by the industry as a whole on applications of grafted polymers, which are produced by monomers being covalently bonded and polymerised as side chains onto the main polymer chain (the backbone).
In 2020, the Group launched a new division named GraftBio to develop IP for Bio/Pharma applications. This includes a drug delivery system to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic. The GraftBio division has been granted HACCP certification for its production facility. The Group has developed a set of drug delivery platforms that enable it to licence its DDS platform (IP) to MGC Pharmaceuticals Limited ("MGC"; LSE: MXC) in relation to MGC's CimetrA™ and CannEpil-IL™ products. The Group expects to receive royalty payments resulting from the sale by MGC of CimetrA™ and CannEpil-IL™ products.